2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Gynecologic
1
CNS
1
Conditions
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Precancerous Conditions
1
Neoplasms by Site
1
Neoplasms
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Genital Diseases
1
Female Urogenital Diseases and Pregnancy Complications
1
Interventions
Paclitaxel
581
Carboplatin
528
Cisplatin
359
Bevacizumab
256
pembrolizumab
228
Gemcitabine
157
liposomal doxorubicin
132
Topotecan
131
olaparib
129
Cyclophosphamide
128
Radiotherapy
118
Taxes
114
Docetaxel
95
Brachytherapy
94
Drug Therapy
91
niraparib
88
Doxorubicin
86
Surveys and Questionnaires
85
Magnetic Resonance Spectroscopy
80
Blood Specimen Collection
74
Nivolumab
71
Specimen Handling
70
Hyperthermic Intraperitoneal Chemotherapy
64
Biopsy
63
fludarabine
57
Filgrastim
53
Letrozole
50
Oxaliplatin
49
durvalumab
47
Immunoglobulin G
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pregnancy Tests
×
Gynecologic
×
Clear all
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled